ABSTRACT
Insulin-like growth factor-I (IGF-I) stimulates proliferation and differentiation of many cell types, including preadipocytes. We have previously shown that IGF-I stimulates proliferation of 3T3-L1 preadipocytes through activation of the extracellular regulated kinase (ERK)-1 and -2 mitogen-activated protein kinase (MAPK) pathway, and that IGF-I-stimulated MAPK is predominantly downstream of Shc, not IRS-1 phosphorylation. The Src family of nonreceptor tyrosine kinases has been shown to mediate the mitogenic effects of other growth factors that also activate Shc and the ERK-1 and -2 MAPKs. Although Src family kinases (SFK) have been implicated in IGF-I action, no specific role for SFKs in IGF-I regulation of mitogenesis has been previously demonstrated. We studied the role of SFKs in IGF-I mitogenic signaling in 3T3-L1 preadipocytes. The SFK-selective inhibitor PP1 completely inhibited both IGF-I-stimulated DNA synthesis and MAPK activation in proliferating 3T3-L1 cells. PP1 inhibited IGF-I phosphorylation of Shc but not of IRS-1. In addition, IGF-I activation of MAPK was inhibited in proliferating cells transiently transfected with a dominant-negative c-Src. Finally, the kinetics of SFK and MAPK activation by IGF-I suggest that SFKs may act upstream of MAPK. IGF-I activation of SFK members c-Src and Fyn occurred within 1 min of treatment, and activity was back to baseline by 10 min. Our previous studies found that IGF-I activation of MAPK peaked at 5 min and was also back to baseline by 10 min. Our results are the first to demonstrate that SFKs mediate IGF-I mitogenic signaling in 3T3-L1 cells and add to the growing body of evidence that SFKs play a crucial role in IGF-I action.
Subject(s)
Cell Division/physiology , Insulin-Like Growth Factor I/metabolism , MAP Kinase Signaling System/physiology , src-Family Kinases/metabolism , 3T3 Cells , Animals , DNA/biosynthesis , Enzyme Inhibitors/pharmacology , Immunoblotting , Insulin Receptor Substrate Proteins , MAP Kinase Signaling System/drug effects , Mice , Mitogen-Activated Protein Kinases/metabolism , Phosphoproteins/metabolism , Precipitin Tests , Pyrazoles/pharmacology , Pyrimidines/pharmacology , Virulence Factors, Bordetella/pharmacology , src-Family Kinases/antagonists & inhibitorsABSTRACT
A 7.5-yr-old boy with Graves' disease, difficult to control with antithyroid medication and radioactive iodine (RAI) therapy, developed thyroid storm encephalopathy on day 13 after withdrawal of methimazole therapy, 4 days after iodine-131 treatment. We attributed his thyroid storm to withdrawal of antithyroid medication as opposed to RAI therapy. We interpret this case as indicating that there may be a need to reevaluate the duration of antithyroid medication withdrawal before RAI therapy for hyperthyroid children at increased risk for thyroid storm.
Subject(s)
Antithyroid Agents/adverse effects , Graves Disease/therapy , Iodine Radioisotopes/adverse effects , Substance Withdrawal Syndrome/etiology , Thyroid Crisis/etiology , Child , Humans , MaleABSTRACT
Insulin-like growth factor-I (IGF-I) stimulates mitogenesis in proliferating preadipocytes, but when cells reach confluence and become growth arrested, IGF-I stimulates differentiation into adipocytes. IGF-I induces signaling pathways that involve IGF-I receptor-mediated tyrosine phosphorylation of Shc and insulin receptor substrate 1 (IRS-1). Either of these adaptor proteins can lead to activation of the three-kinase cascade ending in activation of the extracellular signal-regulated kinase 1 and -2 (ERK-1 and -2) mitogen-activated protein kinases (MAPKs). Several lines of evidence suggest that activation of MAPK inhibits 3T3-L1 preadipocyte differentiation. We have shown that IGF-I stimulation of MAPK activity is lost as 3T3-L1 preadipocytes begin to differentiate. This change in MAPK signaling coincides with loss of IGF-I-mediated Shc, but not IRS-1, tyrosine phosphorylation. We hypothesized that down-regulation of MAPK via loss of proximal signaling through Shc is an early component in the IGF-I switch from mitogenesis to differentiation in 3T3-L1 preadipocytes. Treatment of subconfluent cells with the MEK inhibitor PD098059 inhibited both IGF-I-activation of MAPK as well as 3H-thymidine incorporation. PD098059, in the presence of differentiation-inducing media, accelerated differentiation in subconfluent cells as measured by expression of adipocyte protein-2 (aP-2), peroxisome proliferator-activated receptor gamma (PPARgamma) and lipoprotein lipase (LPL). Transient transfection of subconfluent cells with Shc-Y317F, a dominant-negative mutant, attenuated IGF-I-mediated MAPK activation, inhibited DNA synthesis, and accelerated expression of differentiation markers aP-2, PPARgamma, and LPL. We conclude that signaling through Shc to MAPK plays a critical role in mediating IGF-I-stimulated 3T3-L1 mitogenesis. Our results suggest that loss of the ability of IGF-I to activate Shc signaling to MAPK may be an early component of adipogenesis in 3T3-L1 cells.
Subject(s)
Adaptor Proteins, Signal Transducing , Adaptor Proteins, Vesicular Transport , Adipocytes/cytology , Cell Differentiation , Insulin-Like Growth Factor I/pharmacology , Mitosis , Proteins/physiology , Stem Cells/cytology , 3T3 Cells , Animals , Blotting, Northern , Cell Differentiation/drug effects , Cell Division/drug effects , Culture Media , DNA/biosynthesis , Enzyme Inhibitors/pharmacology , Flavonoids/pharmacology , Mice , Mitogen-Activated Protein Kinases/antagonists & inhibitors , Mutation , Proteins/genetics , Recombinant Fusion Proteins/pharmacology , Reverse Transcriptase Polymerase Chain Reaction , Shc Signaling Adaptor Proteins , Src Homology 2 Domain-Containing, Transforming Protein 1 , TransfectionABSTRACT
The mechanisms responsible for the resistance to the anabolic actions of IGF-I induced by zinc deficiency are not understood. We showed that zinc chelation by DTPA (diethylenetriaminepenta-acetic acid) inhibits [3H]thymidine incorporation stimulated by IGF-I in Rat-1 fibroblasts. This inhibition was specific of zinc chelation since it was prevented by the addition of zinc to DTPA. The stimulation of MAPK, which is crucial for the [3H]thymidine incorporation induced by IGF-I in Rat-1 cells, was partially blunted by DTPA. Therefore, the inhibition of the mitogenic action of IGF-I in Rat-1 fibroblasts by DTPA is potentially caused by decreased MAPK activation by IGF-I.
Subject(s)
Calcium-Calmodulin-Dependent Protein Kinases/metabolism , Insulin-Like Growth Factor I/metabolism , Zinc/metabolism , Animals , Cell Division , Cell Line , Chelating Agents/pharmacology , Enzyme Activation , Fibroblasts/drug effects , Fibroblasts/metabolism , Insulin-Like Growth Factor I/antagonists & inhibitors , Isotope Labeling , Pentetic Acid/pharmacology , Rats , TritiumABSTRACT
A 16-year-old boy with insulin-dependent diabetes mellitus (IDDM) and a history of marginal glycemic control had severe hypoglycemia unawareness and a marked decrease in insulin requirement. His counterregulatory hormone response at the time of hypoglycemia suggested adrenocortical and adrenomedullary dysfunction. Further testing confirmed Addison disease. The patient's hypoglycemia unawareness was reversed by glucocorticoid replacement, although the plasma epinephrine response to hypoglycemia remained undetectable.
Subject(s)
Addison Disease/complications , Diabetes Mellitus, Type 1/complications , Hypoglycemia/etiology , Addison Disease/blood , Adolescent , Adrenocorticotropic Hormone/blood , Blood Glucose , Diabetes Mellitus, Type 1/physiopathology , Epinephrine/blood , Glucocorticoids/therapeutic use , Humans , Hypoglycemia/drug therapy , Male , PerceptionABSTRACT
Insulin-like growth factor I (IGF-I) stimulates mitogenesis in proliferating 3T3-L1 preadipocytes. However, IGF-I functions to stimulate differentiation once growth arrest occurs at confluence. Epidermal growth factor (EGF) is also a potent mitogen in these cells, but inhibits differentiation of preadipocytes. We compared mitogenic signaling via the mitogen-activated protein kinase (MAPK) pathway in response to IGF-I or EGF in proliferating, growth-arrested, and differentiating 3T3-L1 cells. IGF-I stimulation of MAPK was rapid and maximal in proliferating 3T3-L1 preadipocytes, but decreased greatly in differentiating cells. EGF was more potent than IGF-I in stimulating MAPK activity in 3T3-L1 cells, and activation of MAPK was maintained in differentiating cells. These results suggest an uncoupling of MAPK activation specific to IGF-I-mediated 3T3-L1 preadipocyte differentiation. Studies of proximal signaling revealed Shc phosphorylation and Shc/Grb2 complex formation in IGF-I-treated proliferating, but not differentiating, cells. Insulin receptor substrate-1 phosphorylation after IGF-I treatment was present in proliferating, quiescent, and differentiating preadipocytes. Shc phosphorylation and Grb2 association after EGF treatment were present throughout all phases of growth. The change in IGF-I signaling via Shc phosphorylation and MAPK activity during 3T3-L1 differentiation indicates that loss of IGF-I mitogenic signaling via the MAPK pathway is part of the differentiation process.
Subject(s)
Adaptor Proteins, Signal Transducing , Adaptor Proteins, Vesicular Transport , Adipocytes/cytology , Cell Differentiation , Insulin-Like Growth Factor I/pharmacology , Mitogens/pharmacology , Signal Transduction , 3T3 Cells , Animals , Calcium-Calmodulin-Dependent Protein Kinases/metabolism , Cell Division , Enzyme Activation/drug effects , Epidermal Growth Factor/pharmacology , GRB2 Adaptor Protein , Insulin/pharmacology , Kinetics , Mice , Phosphorylation , Proteins/metabolism , Shc Signaling Adaptor Proteins , Src Homology 2 Domain-Containing, Transforming Protein 1 , src Homology DomainsABSTRACT
Preadipocyte factor-1 (Pref-1), a novel gene product isolated from murine preadipocyte 3T3-L1 cells, is thought to function as a negative regulator of adipocyte differentiation. We investigated the regulation of Pref-1 expression in 3T3-L1 preadipocytes during proliferation, growth arrest, and early differentiation in the presence and absence of three well described differentiation antagonists: interleukin-11 (IL-11), transforming growth factor-beta, and tumor necrosis factor-alpha. Northern blot analysis was used to determine messenger RNA (mRNA) steady state expression of Pref-1 and two differentiation-specific genes, adipsin and glycerol-3-phosphate dehydrogenase. We confirmed that Pref-1 mRNA is abundant in proliferating preadipocytes and that its expression is dramatically reduced early in differentiation. However, proliferating and growth-arrested cells treated with the differentiation inhibitor IL-11 demonstrated a modest decrease in Pref-1 mRNA abundance. Transforming growth factor-beta and tumor necrosis factor-alpha had little effect. The reduction of Pref-1 mRNA was most dramatic in differentiating preadipocytes treated with IL-11, occurring despite inhibition of adipogenesis, as judged by cell morphology and adipocyte-specific gene expression (adipsin and glycerol-3-phosphate dehydrogenase). This effect of IL-11 on Pref-1 suggests that different mechanisms are responsible for the IL-11-induced and the differentiation- associated down-regulation of Pref-1, thus dissociating Pref-1 regulation from differentiation. We conclude that Pref-1 expression is not a reliable marker of preadipocytes, and that decreased Pref-1 abundance does not function as a trigger for adipocyte differentiation.
Subject(s)
Adipocytes/cytology , Cell Differentiation , Gene Expression Regulation , Membrane Proteins/biosynthesis , Repressor Proteins/biosynthesis , 1-Methyl-3-isobutylxanthine/pharmacology , 3T3 Cells , Adipocytes/metabolism , Animals , Base Sequence , Blotting, Northern , Calcium-Binding Proteins , Cell Division/drug effects , Complement Factor D , DNA Primers , DNA, Complementary , Dexamethasone/pharmacology , Gene Expression Regulation/drug effects , Glycerolphosphate Dehydrogenase/biosynthesis , Insulin/pharmacology , Intercellular Signaling Peptides and Proteins , Interleukin-1/pharmacology , Kinetics , Mice , Molecular Sequence Data , Polymerase Chain Reaction , RNA, Messenger/metabolism , Serine Endopeptidases/biosynthesis , Transcription, Genetic/drug effects , Transforming Growth Factor beta/pharmacology , Tumor Necrosis Factor-alpha/pharmacologyABSTRACT
Insulin-like growth factor-I (IGF-I) stimulates the differentiation of preadipocytes, but the expression of IGF-I and IGF-binding proteins (IGFBPs) during the course of adipogenesis has not been investigated. Using two in vitro models, primary mouse preadipocytes and the 3T3-L1 preadipocyte cell line stimulated to differentiate with IGF-I, we studied IGF and IGFBP expression before and during differentiation. Primary preadipocyte cultures expressed IGF-I, IGFBP-2, and IGFBP-4 messenger RNAs (mRNAs), and conditioned medium (CM) contained IGFBP-3 [approximately 46,000 mol wt (M(r))], IGFBP-4 (24,000 M(r)), and a 30,000 M(r) IGFBP identified by immunoblot as IGFBP-2. During differentiation, an additional approximately 34,000 M(r) form of IGFBP-2 was predominant, but IGFBP-2 mRNA decreased, suggesting that a mechanism other than steady state mRNA levels is regulating protein abundance in CM. Like primary cultures, undifferentiated 3T3-L1 cells expressed IGFBP-4 mRNA, but insignificant levels of IGF-I and IGFBP-2 mRNAs. 3T3-L1 cell CM contained IGFBP-3 and IGFBP-4, and with the addition of IGF-I, a 30,000 M(r) IGFBP was also present. This IGFBP was not recognized by antiserum to IGFBP-1, -2, -4, -5, or -6. During differentiation of 3T3-L1 cells, an approximately 34,000 M(r) form of IGFBP-2 was also present in CM. In summary, primary cultures of mouse preadipocytes and 3T3-L1 cells express similar IGFBPs during IGF-I-stimulated adipogenesis. The presence of a larger isoform of IGFBP-2 in a differentiation-dependent manner and a potentially novel IGFBP in response to IGF-I suggests that these IGFBPs may be important in modulating IGF-I action in adipogenesis.
Subject(s)
Adipocytes/chemistry , Adipocytes/cytology , Adipose Tissue/chemistry , Adipose Tissue/cytology , Carrier Proteins/analysis , Carrier Proteins/physiology , Insulin-Like Growth Factor I/analysis , Insulin-Like Growth Factor I/physiology , Stem Cells/chemistry , Stem Cells/cytology , Adipocytes/metabolism , Adipose Tissue/metabolism , Animals , Blotting, Northern , Carrier Proteins/genetics , Cell Differentiation/physiology , Cell Division/physiology , Cell Line , Insulin-Like Growth Factor Binding Protein 1 , Insulin-Like Growth Factor Binding Protein 2 , Insulin-Like Growth Factor Binding Protein 4 , Insulin-Like Growth Factor Binding Proteins , Insulin-Like Growth Factor I/genetics , Mice , Polymerase Chain Reaction , RNA, Messenger/analysis , RNA, Messenger/genetics , RNA, Messenger/metabolism , Stem Cells/metabolismABSTRACT
Three lines of transgenic (Tg) mice carrying a fusion gene linking the mouse metallothionein-I promoter to a cDNA encoding human insulin-like growth factor binding protein-1 (hIGFBP-1) were found to express the transgene in brain. As judged by comparing Tg brain weights to those of non-transgenic littermates, adult hemizygotic Tg mice of each line exhibited brain growth retardation (16.2%, 14.4% and 8.1% reductions in weight, respectively in each line). In two lines, total brain DNA and protein content were decreased. Further analysis indicated that the brain growth retardation was manifested in the second week of postnatal life. Given that the insulin-like growth factors (IGFs) stimulate cell proliferation and/or survival in neural cultures and that hIGFBP-1, when present in a molar excess, inhibits IGF interactions with their cell surface receptors, the brain growth retardation in hIGFBP-1 Tg mice likely results from hIGFBP-1 inhibition of IGF-stimulated growth-promoting actions. These hIGFBP-1 Tg mice should prove useful in defining IGF actions during postnatal brain maturation.
Subject(s)
Aging/metabolism , Brain/growth & development , Carrier Proteins/biosynthesis , Insulin-Like Growth Factor II/physiology , Insulin-Like Growth Factor I/physiology , Animals , Base Sequence , Brain/metabolism , Carrier Proteins/analysis , Carrier Proteins/genetics , DNA Primers , DNA, Complementary , Female , Gene Expression , Genotype , Humans , Immunohistochemistry , In Situ Hybridization , Insulin-Like Growth Factor Binding Protein 1 , Liver/growth & development , Liver/metabolism , Male , Mice , Mice, Transgenic , Molecular Sequence Data , Organ Size , Organ Specificity , Polymerase Chain Reaction , Sex CharacteristicsABSTRACT
Three hemizygous transgenic (Tg) mouse lines were generated with a fusion gene composed of the mouse metallothionein promoter (mMT-I) and a full-length human insulin-like growth factor binding protein-1 (hIGFBP-1) complementary DNA that was truncated in its 3'-untranslated region. Despite high serum hIGFBP-1 levels (120-2570 micrograms/liter) before puberty in two of these lines, no significant alterations were observed in somatic growth, nor were marked alterations noted in fasting or random serum glucose or in the response of young adult Tg mice to ip glucose. The transgene was expressed in a number of tissues from each line, but liver was a significant site of transgene expression in only one line. Unexpectedly, liver hIGFBP-1 messenger RNA (mRNA) expression in this line was regulated in fashion similar to the native liver IGFBP-1 mRNA: 1) its abundance waned with advancing postnatal age and became minimal in early adult life, despite continuous zinc supplementation to stimulate its transcription; and 2) fasting increased its abundance 3- to 4.3-fold. The decline in transgene expression with aging was not due to a deletion, rearrangement, or a change in the methylation of liver transgene DNA. Transcriptional mechanisms also were not likely to account for the observed regulation of the transgene mRNA, because liver expression of the mMT-I gene, which shares identical genomic 5'-regulatory elements with the transgene, was not similarly altered by aging or fasting. Because cycloheximide (CHX) treatment of cultured rat H4IIE cells has been shown to prolong IGFBP-1 mRNA half-life while decreasing its transcription, Tg mice were treated with CHX to test the possibility that instability of the liver transgene mRNA influenced its abundance. After CHX and under conditions of chronic zinc supplementation, liver transgene mRNA abundance increased in parallel with that of the native IGFBP-1 mRNA. Although CHX is known to activate mMT-I transcription by mechanisms involving the 5'-regulatory regions contained in the transgene, CHX-induced transcription only in part accounted for the increase in liver transgene mRNA, because CHX induced an earlier and greater increase in liver transgene mRNA than in mMT-I mRNA. Taken together, these data indicate that both transgene and native IGFBP-1 liver mRNA are regulated by factors that alter mRNA stability. The finding that native liver IGFBP-1 mRNA abundance is influenced by transgene expression further supports the concept that both mRNAs share some common mechanisms of regulation.(ABSTRACT TRUNCATED AT 400 WORDS)
Subject(s)
Carrier Proteins/genetics , Animals , Base Sequence , Blotting, Northern , Blotting, Southern , Brain Chemistry , Carrier Proteins/analysis , Carrier Proteins/blood , Cycloheximide/pharmacology , DNA/analysis , DNA/genetics , Fasting , Gene Expression Regulation , Insulin-Like Growth Factor Binding Protein 1 , Liver/chemistry , Lung/chemistry , Male , Mice , Mice, Inbred C3H , Mice, Inbred C57BL , Mice, Transgenic , Molecular Sequence Data , Phenotype , Polymerase Chain Reaction , RNA, Messenger/analysis , RNA, Messenger/genetics , Radioimmunoassay , Testis/chemistryABSTRACT
McCune-Albright syndrome (MCAS) is a sporadic disease classically including polyostotic fibrous dysplasia, café au lait spots, sexual precocity, and other hyperfunctional endocrinopathies. An activating missense mutation in the gene for the alpha subunit of GS, the G protein that stimulates cyclic adenosine monophosphate formation, has been reported to be present in these patients. The mutation is found in variable abundance in different affected endocrine and nonendocrine tissues, consistent with the mosaic distribution of abnormal cells generated by a somatic cell mutation early in embryogenesis. We describe three patients with MCAS who had profound endocrine and nonendocrine disease and who died in childhood. Two of the patients were severely ill neonates whose complex symptoms did not immediately suggest MCAS. A mutation of residue Arg201 of GS alpha was found in affected tissues from all three children. A review of the literature and unpublished case histories emphasizes the existence of other patients with severe and unusual clinical manifestations. We conclude that the manifestations of MCAS are more extensive than is generally appreciated, and may include hepatobiliary disease, cardiac disease, other nonendocrine abnormalities, and sudden or premature death.
Subject(s)
Arginine/genetics , Fibrous Dysplasia, Polyostotic/genetics , GTP-Binding Proteins/genetics , Adolescent , Antisense Elements (Genetics) , Cyclic AMP/genetics , Death, Sudden/epidemiology , Endocrine System Diseases/genetics , Female , Fibrous Dysplasia, Polyostotic/complications , Humans , Infant, Newborn , Male , Mosaicism , Mutation , Polymerase Chain Reaction , Risk FactorsABSTRACT
Investigation of platelet function in dogs with cyclic hematopoiesis (CH) revealed a platelet aggregation disorder. Collagen-induced aggregation of CH dog platelets was significantly abnormal, although normal aggregation in response to ADP was observed. Aggregation was particularly defective on days 2-4 and 14 of the 14-day neutrophil cycle that is typical of CH dogs. The lack of response to collagen suggested a defect in the arachidonic acid pathway of platelet metabolism, since platelet-generated thromboxane-B2 levels were about 30% (p less than 0.0005) of control values. Platelets from dogs heterozygous for CH demonstrated moderately depressed responses to collagen that were intermediate between the values found for platelets from CH dogs and platelets from normal, mixed-breed dogs. Not only does this work indicate a platelet defect in CH dogs, but this phenomenon may be useful as a genetic marker for identification of dogs heterozygous for the CH gene.
Subject(s)
Blood Platelets/physiopathology , Dog Diseases/physiopathology , Hematopoietic System/physiology , Thromboxanes/blood , Adenosine Diphosphate/pharmacology , Animals , Blood Platelets/metabolism , Collagen/pharmacology , Dog Diseases/genetics , Dogs , Female , Heterozygote , Male , Neutropenia/complications , Platelet Aggregation/drug effectsABSTRACT
Three tripeptidyl polyoxins were synthesized and found to inhibit Candida albicans. Compared with the naturally occurring polyoxin D, the three synthetic polyoxins had little effect on chitin synthetase when assayed with a C. albicans membrane preparation. However, all the compounds inhibited growth, affected cell morphology in a manner similar to that of polyoxin D, and were hydrolyzed by cell extracts of C. albicans. Hydrolysis did not occur extracellularly, and at least one of the synthetic polyoxins, leucyl-norleucyl-uracil polyoxin C, inhibited peptide uptake, suggesting entrance into the cell via the peptide transport system. Thus, the intact tripeptidyl polyoxins are inactive prodrugs that are converted to active moieties by cellular enzymes.
Subject(s)
Antifungal Agents/chemical synthesis , Candida albicans/drug effects , Candida albicans/metabolism , Chitin Synthase/metabolism , Oligopeptides/chemical synthesis , Oligopeptides/pharmacology , Peptides/chemical synthesis , Peptides/pharmacology , Pyrimidine Nucleosides/chemical synthesis , Pyrimidine Nucleosides/pharmacologyABSTRACT
The effect of purified beef heart cAMP-dependent protein kinase catalytic subunit on tyrosine aminotransferase activity in intact cultured rat H35 hepatoma cells was directly tested by micro-injection using human red blood cell ghosts as vehicles. Although the micro-injection procedure itself produced temporary fluctuations in protein synthesis and in tyrosine aminotransferase activity in H35 cells, after a recovery period of 8-12 h, these parameters returned to normal in parallel with restoration of full inducibility of the aminotransferase by both 8-Br-cAMP and dexamethasone. Eight to sixteen hours after fusion of H35 cells with unloaded ghosts, ghosts loaded with bovine serum albumin or mock-loaded with the partially purified protein kinase catalytic subunit, no significant change in the activity of the aminotransferase was detected. In contrast, fusion with ghosts loaded with the catalytic subunit at concentrations between 0.1-2 mg/ml caused reproducible 2-3-fold increases in enzyme activity. Homogeneous preparations of the catalytic subunit exhibited even greater potency as an inducer. The effect was both time- and concentration-dependent and was abolished by inactivation of the catalytic subunit with N-ethylmaleimide prior to loading. The partially purified inhibitor of protein kinase from beef heart, while not affecting basal tyrosine aminotransferase activity, selectively inhibited the ability of 8-Br-cAMP but not that of dexamethasone to stimulate the activity of this enzyme. In addition, micro-injection of the pure regulatory subunit of the kinase blocked the response of the aminotransferase to low concentrations of 8-Br-cAMP. These results provide strong support for the proposition that the catalytic subunit of protein kinase mediates the effects of cAMP on the synthesis of tyrosine aminotransferase.